[
  {
    "ts": null,
    "headline": "Biogen Inc. Announces New Data for Nusinersen Underscore Biogen's Commitment to Advancing Clinical Research to Improve Outcomes in SMA",
    "summary": "Biogen Inc. announced new data that reinforce the clinical impact of nusinersen across a broad spectrum of individuals affected by spinal muscular atrophy . These latest findings from Part C of the...",
    "url": "https://finnhub.io/api/news?id=c30a809f024a3f93f766f041a7bce74afa24d0c824855a850b368803e524aee5",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751043938,
      "headline": "Biogen Inc. Announces New Data for Nusinersen Underscore Biogen's Commitment to Advancing Clinical Research to Improve Outcomes in SMA",
      "id": 135597655,
      "image": "",
      "related": "BIIB",
      "source": "Finnhub",
      "summary": "Biogen Inc. announced new data that reinforce the clinical impact of nusinersen across a broad spectrum of individuals affected by spinal muscular atrophy . These latest findings from Part C of the...",
      "url": "https://finnhub.io/api/news?id=c30a809f024a3f93f766f041a7bce74afa24d0c824855a850b368803e524aee5"
    }
  },
  {
    "ts": null,
    "headline": "New Data for Nusinersen Underscore Biogen’s Commitment to Advancing Clinical Research to Improve Outcomes in SMA",
    "summary": "New analyses from DEVOTE Part C further characterize the improvements in motor function in participants with SMA who transitioned to the investigational higher dose regimen of nusinersen from 12 mg SPINRAZA® (nusinersen) Final results from the landmark NURTURE study highlight the profound impact of early treatment with 12 mg SPINRAZA in clinically presymptomatic SMA with 92% of children achieving the ability to walk independently CAMBRIDGE, Mass., June 27, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (N",
    "url": "https://finnhub.io/api/news?id=e9fc244962285d27818551b0bf6a2b038f7a2927fe78cc084d3021ebc8108a4c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751032800,
      "headline": "New Data for Nusinersen Underscore Biogen’s Commitment to Advancing Clinical Research to Improve Outcomes in SMA",
      "id": 135590773,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "New analyses from DEVOTE Part C further characterize the improvements in motor function in participants with SMA who transitioned to the investigational higher dose regimen of nusinersen from 12 mg SPINRAZA® (nusinersen) Final results from the landmark NURTURE study highlight the profound impact of early treatment with 12 mg SPINRAZA in clinically presymptomatic SMA with 92% of children achieving the ability to walk independently CAMBRIDGE, Mass., June 27, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (N",
      "url": "https://finnhub.io/api/news?id=e9fc244962285d27818551b0bf6a2b038f7a2927fe78cc084d3021ebc8108a4c"
    }
  }
]